Mary Jo Laffler is the U.S. executive editor for Scrip, covering pharmaceutical news for commercial and R&D professionals. Previously, she was executive editor for the Pink Sheet and has been reporting on the pharmaceutical industry for 25 years.
Friday, November 14 at 1:00PM ET
For pharma companies, the weeks immediately before and after FDA submission are critical to launch success. During this pivotal period, missteps can result in several undesirable outcomes at launch, from overestimating your brand’s adoption peak to underestimating the necessary contracting spend.
In this webinar, we’ll discuss five of the largest risks associated with launch. Our experts will explain the concrete steps your team can take to mitigate those risks in advance—so you can launch your therapy without fear of failure.
You will learn:
Mary Jo Laffler is the U.S. executive editor for Scrip, covering pharmaceutical news for commercial and R&D professionals. Previously, she was executive editor for the Pink Sheet and has been reporting on the pharmaceutical industry for 25 years.
Jason Rodman is vice president of Client Partnership at MMIT, where he leverages his background in pharmaceutical analytics and commercial operations to serve MMIT’s strategic clients. Jason has more than 20 years of pharmaceutical industry experience leading client-focused teams, delivering market access strategic initiatives, and building innovative data-driven solutions that simplify patients’ access to care. He holds an MBA from Duke University’s Fuqua School of Business.
Carolyn Zele is an advisor for MMIT’s solution consulting team who helps pharmaceutical manufacturers simplify market access and prepare for launch success. Prior to MMIT, Carolyn spent numerous years in the payer/PBM space managing formulary teams and technology across both regulated and non-regulated lines of business. She holds a Master of Science degree from Colorado State University.